{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:43:20Z","timestamp":1793256200757,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.trecan.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:40:38Z","timestamp":1720582838000},"page":"708-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Current landscape of CD3 bispecific antibodies in hematologic malignancies"],"prefix":"10.1016","volume":"10","author":[{"given":"Joshua","family":"Kassner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Yamshon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2024.06.001_bb0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.trecan.2024.06.001_bb0010","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2024.06.001_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0025","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.06.001_bb0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trecan.2024.06.001_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2083479","article-title":"Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2024.06.001_bb0040","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.804714","article-title":"Real-world multicenter experience in tumor debulking prior to blinatumomab administration in adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"11","author":"Bonifacio","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0050","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.001_bb0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2024.06.001_bb0060","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/cancers15061819","article-title":"Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety","volume":"15","author":"Swan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2024.06.001_bb0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and approaches to overcoming resistance to immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.trecan.2024.06.001_bb0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/PGPM.S399336","article-title":"Construction and validation of a novel nomogram for predicting the recurrence of diffuse large B cell lymphoma treated with R-CHOP","volume":"16","author":"Gong","year":"2023","journal-title":"PGPM"},{"key":"10.1016\/j.trecan.2024.06.001_bb0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0090","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0095","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/blood-2019-129600","article-title":"Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies","volume":"134","author":"Horna","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0100","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2024.06.001_bb0105","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2024.06.001_bb0115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.20.01564","article-title":"Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell-redirected bispecific antibodies","volume":"39","author":"Lussana","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0120","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3\u00d7CD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase 1\/2 trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0125","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1200\/JCO.2022.40.16_suppl.7523","article-title":"First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1\/2 data update","volume":"40","author":"Falchi","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0130","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2022-158203","article-title":"Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: phase 1\/2 trial update","volume":"140","author":"Falchi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0135","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.06.001_bb0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2022-157777","article-title":"Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0145","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2022-158404","article-title":"Odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) grade 1\u20133a: results from a prespecified analysis of the pivotal phase UU study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0150","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1182\/bloodadvances.2022009066","article-title":"The race is on: bispecifics vs CAR T cells in B-cell lymphoma","volume":"7","author":"Gurumurthi","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2024.06.001_bb0155","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.trecan.2024.06.001_bb0165","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.3390\/jcm10184088","article-title":"BCMA in multiple myeloma \u2013 a promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"JCM"},{"key":"10.1016\/j.trecan.2024.06.001_bb0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.06.001_bb0175","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0180","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0185","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0190","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.06.001_bb0195","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2024.06.001_bb0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-023-01461-1","article-title":"Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting","volume":"16","author":"Xia","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0205","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.06.001_bb0210","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0215","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2024.06.001_bb0225","series-title":"International Myeloma Society 20th Annual Meeting and Exposition; September 27\u201330, 2023; Athens, Greece","article-title":"Efficacy of forimtamig, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: analysis of patient- and disease-related factors associated with responses","author":"Harrison","year":"2023"},{"key":"10.1016\/j.trecan.2024.06.001_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: a journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0240","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/JCO.2022.40.16_suppl.8029","article-title":"Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B","volume":"40","author":"van de Donk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0245","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0250","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood-2021-150757","article-title":"A phase 1 first-in-human study of Tnb-383B, a BCMA \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0260","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): updated phase 1b results for daratumumab in combination with teclistamab (a BCMA \u00d7 CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5D\u00d7CD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0270","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.trecan.2024.06.001_bb0275","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0280","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.06.001_bb0285","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2024.06.001_bb0290","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Von Stackelberg","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0295","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0300","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V124.21.379.379","article-title":"BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE\u00ae) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)","volume":"124","author":"Goekbuget","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","article-title":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study","volume":"13","author":"Boissel","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2024.06.001_bb0310","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171751","volume":"140","author":"Litzow","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0315","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"Van Der Sluis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.06.001_bb0320","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0325","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.06.001_bb0330","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/life11060465","article-title":"BiTEs, DARTS, BiKEs and TriKEs \u2013 are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.trecan.2024.06.001_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101224","article-title":"CD33 directed bispecific antibodies in acute myeloid leukemia","volume":"33","author":"Clark","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0340","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.trecan.2024.06.001_bb0345","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2019-129042","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"134","author":"Westervelt","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0350","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) Anti-CD33\/CD3 BiTE\u00ae (bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0355","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.001_bb0360","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-99-119786","article-title":"Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 \u00d7 CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0365","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3\u00d7CD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2024.06.001_bb0370","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.trecan.2024.06.001_bb0375","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.trecan.2024.06.001_bb0380","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003882","article-title":"A novel IgG-based FLT3\u00d7CD3 bispecific antibody for the treatment of AML and B-ALL","volume":"10","author":"Mehta","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2024.06.001_bb0385","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.001_bb0390","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2015.141796","article-title":"Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia","volume":"101","author":"Rampal","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.trecan.2024.06.001_bb0395","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2023-173302","article-title":"Dose escalation of HLA-A2-WT1 CD3 T-cell bispecific antibody in a phase I study in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.001_bb0400","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/cancers15041349","article-title":"Optimal use of novel Immunotherapeutics in B-cell precursor ALL","volume":"15","author":"Lussana","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2024.06.001_bb0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2018.1.16","article-title":"Are CAR T cells better than antibody or HCT therapy in B-ALL?","author":"Pulsipher","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.trecan.2024.06.001_bb0410","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2024.06.001_bb0415","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2022-159353","article-title":"ISB 2001, a first-in-class trispecific BCMA and CD38T cell engager designed to overcome mechanisms of escape from treatments for multiple myeloma by targeting two antigens","volume":"140","author":"Pihlgren","year":"2022","journal-title":"Blood"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803324001158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803324001158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T16:28:08Z","timestamp":1723566488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803324001158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405803324001158"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2024.06.001","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape of CD3 bispecific antibodies in hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}